Effects of hemoglobin C and S traits on the results of 14 commercial glycated hemoglobin assays

Shella K. Mongia; Randie R. Little; Curt L. Rohlfing; Steve Hanson; Richard F. Roberts; William E. Owen; Mario A. D'Costa; Christine A. Reyes; Veronica I. Luzzi; William L. Roberts

doi:10.1309/1YU0D34VJKNUCGT1

Effects of hemoglobin C and S traits on the results of 14 commercial glycated hemoglobin assays

Shella K. Mongia, Randie R. Little, Curt L. Rohlfing, Steve Hanson, Richard F. Roberts, William E. Owen, Mario A. D'Costa, Christine A. Reyes, Veronica I. Luzzi, William L. Roberts

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Abstract

Glycated hemoglobin is widely used in the management of diabetes mellitus. At least 300,000 Americans with diabetes mellitus have the hemoglobin (Hb) C or S trait. The accuracy of HbA 1c methods can be adversely affected by the presence of these traits. We evaluated the effects of HbC and HbS traits on the results of 14 commercial HbA 1c methods that use boronate affinity, enzymatic, immunoassay, and ion exchange methods. Whole blood samples from people homozygous for HbA or heterozygous for HbC or HbS were analyzed for HbA 1c. Results for each sample type were compared with those from the CLC 330 comparative method (Primus Diagnostics, Kansas City, MO). After correcting for calibration bias by comparing results from the homozygous HbA group, method bias attributable to the presence of HbC or HbS trait was evaluated with a clinically significant difference being more than 10% (ie, 0.6% at 6% HbA 1c). One immunoassay method exhibited clinically significant differences owing to the presence of HbC and HbS traits. ©American Society for Clinical Pathology.

Original language	English (US)
Pages (from-to)	136-140
Number of pages	5
Journal	American Journal of Clinical Pathology
Volume	130
Issue number	1
DOIs	https://doi.org/10.1309/1YU0D34VJKNUCGT1
State	Published - Jul 1 2008
Externally published	Yes

Bibliographical note

Generated from Scopus record by KAUST IRTS on 2023-09-20

ASJC Scopus subject areas

Pathology and Forensic Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1309/1YU0D34VJKNUCGT1

Cite this

@article{a7d61292b58c4d4d96e474b7921ddae9,

title = "Effects of hemoglobin C and S traits on the results of 14 commercial glycated hemoglobin assays",

abstract = "Glycated hemoglobin is widely used in the management of diabetes mellitus. At least 300,000 Americans with diabetes mellitus have the hemoglobin (Hb) C or S trait. The accuracy of HbA 1c methods can be adversely affected by the presence of these traits. We evaluated the effects of HbC and HbS traits on the results of 14 commercial HbA 1c methods that use boronate affinity, enzymatic, immunoassay, and ion exchange methods. Whole blood samples from people homozygous for HbA or heterozygous for HbC or HbS were analyzed for HbA 1c. Results for each sample type were compared with those from the CLC 330 comparative method (Primus Diagnostics, Kansas City, MO). After correcting for calibration bias by comparing results from the homozygous HbA group, method bias attributable to the presence of HbC or HbS trait was evaluated with a clinically significant difference being more than 10% (ie, 0.6% at 6% HbA 1c). One immunoassay method exhibited clinically significant differences owing to the presence of HbC and HbS traits. {\textcopyright}American Society for Clinical Pathology.",

author = "Mongia, {Shella K.} and Little, {Randie R.} and Rohlfing, {Curt L.} and Steve Hanson and Roberts, {Richard F.} and Owen, {William E.} and D'Costa, {Mario A.} and Reyes, {Christine A.} and Luzzi, {Veronica I.} and Roberts, {William L.}",

note = "Generated from Scopus record by KAUST IRTS on 2023-09-20",

year = "2008",

month = jul,

day = "1",

doi = "10.1309/1YU0D34VJKNUCGT1",

language = "English (US)",

volume = "130",

pages = "136--140",

journal = "American Journal of Clinical Pathology",

issn = "0002-9173",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Effects of hemoglobin C and S traits on the results of 14 commercial glycated hemoglobin assays

AU - Mongia, Shella K.

AU - Little, Randie R.

AU - Rohlfing, Curt L.

AU - Hanson, Steve

AU - Roberts, Richard F.

AU - Owen, William E.

AU - D'Costa, Mario A.

AU - Reyes, Christine A.

AU - Luzzi, Veronica I.

AU - Roberts, William L.

N1 - Generated from Scopus record by KAUST IRTS on 2023-09-20

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Glycated hemoglobin is widely used in the management of diabetes mellitus. At least 300,000 Americans with diabetes mellitus have the hemoglobin (Hb) C or S trait. The accuracy of HbA 1c methods can be adversely affected by the presence of these traits. We evaluated the effects of HbC and HbS traits on the results of 14 commercial HbA 1c methods that use boronate affinity, enzymatic, immunoassay, and ion exchange methods. Whole blood samples from people homozygous for HbA or heterozygous for HbC or HbS were analyzed for HbA 1c. Results for each sample type were compared with those from the CLC 330 comparative method (Primus Diagnostics, Kansas City, MO). After correcting for calibration bias by comparing results from the homozygous HbA group, method bias attributable to the presence of HbC or HbS trait was evaluated with a clinically significant difference being more than 10% (ie, 0.6% at 6% HbA 1c). One immunoassay method exhibited clinically significant differences owing to the presence of HbC and HbS traits. ©American Society for Clinical Pathology.

AB - Glycated hemoglobin is widely used in the management of diabetes mellitus. At least 300,000 Americans with diabetes mellitus have the hemoglobin (Hb) C or S trait. The accuracy of HbA 1c methods can be adversely affected by the presence of these traits. We evaluated the effects of HbC and HbS traits on the results of 14 commercial HbA 1c methods that use boronate affinity, enzymatic, immunoassay, and ion exchange methods. Whole blood samples from people homozygous for HbA or heterozygous for HbC or HbS were analyzed for HbA 1c. Results for each sample type were compared with those from the CLC 330 comparative method (Primus Diagnostics, Kansas City, MO). After correcting for calibration bias by comparing results from the homozygous HbA group, method bias attributable to the presence of HbC or HbS trait was evaluated with a clinically significant difference being more than 10% (ie, 0.6% at 6% HbA 1c). One immunoassay method exhibited clinically significant differences owing to the presence of HbC and HbS traits. ©American Society for Clinical Pathology.

UR - https://academic.oup.com/ajcp/article-lookup/doi/10.1309/1YU0D34VJKNUCGT1

UR - http://www.scopus.com/inward/record.url?scp=48249157956&partnerID=8YFLogxK

U2 - 10.1309/1YU0D34VJKNUCGT1

DO - 10.1309/1YU0D34VJKNUCGT1

M3 - Article

SN - 0002-9173

VL - 130

SP - 136

EP - 140

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

IS - 1

ER -

Effects of hemoglobin C and S traits on the results of 14 commercial glycated hemoglobin assays

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this